Determination of clinically therapeutic endoxifen concentrations based on efficacy from human MCF7 breast cancer xenografts

CYP3A4 and seasonal variation in vitamin D status in addition to CYP2D6 contribute to therapeutic endoxifen level during tamoxifen therapy

(2013) Wendy A. Teft et al.   BREAST CANCER RESEARCH AND TREATMENT

Antitumor Activity of Targeted and Cytotoxic Agents in Murine Subcutaneous Tumor Models Correlates with Clinical Response

(2012) H. Wong et al.   CLINICAL CANCER RESEARCH

CYP2D6 and UGT2B7 Genotype and Risk of Recurrence in Tamoxifen-Treated Breast Cancer Patients

(2012) James M. Rae et al.   JNCI-Journal of the National Cancer Institute

CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women with Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial

(2012) Meredith M. Regan et al.   JNCI-Journal of the National Cancer Institute

Dose-adjustment study of tamoxifen based on CYP2D6 genotypes in Japanese breast cancer patients

(2011) Kazuma Kiyotani et al.   BREAST CANCER RESEARCH AND TREATMENT

Increasing Tamoxifen Dose in Breast Cancer Patients Based on CYP2D6 Genotypes and Endoxifen Levels: Effect on Active Metabolite Isomers and the Antiestrogenic Activity Score

(2011) M F Barginear et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Activity Levels of Tamoxifen Metabolites at the Estrogen Receptor and the Impact of Genetic Polymorphisms of Phase I and II Enzymes on Their Concentration Levels in Plasma

(2011) T E Mürdter et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Tamoxifen Metabolite Concentrations, CYP2D6 Genotype, and Breast Cancer Outcomes

(2011) L Madlensky et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Genotype-Guided Tamoxifen Dosing Increases Active Metabolite Exposure in Women With Reduced CYP2D6 Metabolism: A Multicenter Study

(2011) William J. Irvin et al.   JOURNAL OF CLINICAL ONCOLOGY

Orally administered Endoxifen is a new therapeutic agent for breast cancer

(2010) Ateeq Ahmad et al.   BREAST CANCER RESEARCH AND TREATMENT

CYP2D6 Polymorphisms as Predictors of Outcome in Breast Cancer Patients Treated with Tamoxifen: Expanded Polymorphism Coverage Improves Risk Stratification

(2010) W. Schroth et al.   CLINICAL CANCER RESEARCH

Endoxifen, a New Cornerstone of Breast Cancer Therapy: Demonstration of Safety, Tolerability, and Systemic Bioavailability in Healthy Human Subjects

(2010) A Ahmad et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

The CYP2D6*4 polymorphism affects breast cancer survival in tamoxifen users

(2009) Monique J. Bijl et al.   BREAST CANCER RESEARCH AND TREATMENT

The Tamoxifen Metabolite, Endoxifen, Is a Potent Antiestrogen that Targets Estrogen Receptor   for Degradation in Breast Cancer Cells

(2009) X. Wu et al.   CANCER RESEARCH

Association Between CYP2D6 Polymorphisms and Outcomes Among Women With Early Stage Breast Cancer Treated With Tamoxifen

(2009) Werner Schroth   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Genotype-guided tamoxifen therapy: time to pause for reflection?

(2009) Timothy L Lash et al.   LANCET ONCOLOGY

Vascular Endothelial Growth Factor Reduces Tamoxifen Efficacy and Promotes Metastatic Colonization and Desmoplasia in Breast Tumors

(2008) Z. Qu et al.   CANCER RESEARCH

Impact of CYP2D6*10 on recurrence-free survival in breast cancer patients receiving adjuvant tamoxifen therapy

(2008) Kazuma Kiyotani et al.   CANCER SCIENCE

Impaired Tamoxifen Metabolism Reduces Survival in Familial Breast Cancer Patients

(2008) W. G. Newman et al.   CLINICAL CANCER RESEARCH

Pharmacogenomic Variation of CYP2D6 and the Choice of Optimal Adjuvant Endocrine Therapy for Postmenopausal Breast Cancer: A Modeling Analysis

(2008) R. S. Punglia et al.   JNCI-Journal of the National Cancer Institute

Impact of pH on Plasma Protein Binding in Equilibrium Dialysis

(2008) Christopher J. Kochansky et al.   MOLECULAR PHARMACEUTICS